Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysis.
Adv TherJun 12, 2026 (epub)
Joseph K Han, Joaquim Mullol, Claire Hopkins et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic literature review and network meta-analysis evaluated the efficacy of tezepelumab compared to other biologics and endoscopic sinus surgery in adults with severe chronic rhinosinusitis with nasal polyps. At 52 weeks, tezepelumab demonstrated comparable efficacy to dupilumab across all endpoints, except for a lower surgery rate, where it outperformed dupilumab.
Key findings
- Tezepelumab showed a lower proportion of patients requiring surgery compared to dupilumab.
- Tezepelumab consistently outperformed mepolizumab, depemokimab, and placebo.
- In analyses of <30-week endpoints, tezepelumab outperformed omalizumab for all outcomes except SNOT-22.
Why it matters
Understanding the comparative efficacy of tezepelumab against other treatments can guide clinicians in selecting appropriate therapies for patients with severe chronic rhinosinusitis with nasal polyps, potentially improving patient outcomes.